🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

8 recruiting trials

for Resectable Hepatocellular Carcinoma With High Risk of Recurrence

HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence NCT06812039Phase 23 sites📍 Fuzhou📍 Shanghai📍 Tianjin Fudan University · Tests: HAIC combined with sintilimab and donafenib, Sintilimab and Donafenib, Surgery Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo NCT07239245Phase 24 sites📍 Beijing📍 Zhengzhou📍 Shenyang Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Atezolizumab, Bevacizumab, Transarterial chemoembolization (TACE) The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) NCT07064681n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: Surgery with and without the aid of Indocyanine Green (ICG) A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk NCT06930573Phase 41 site📍 Zhengzhou The First Affiliated Hospital of Zhengzhou University · Tests: AK112 A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence NCT07475026Phase 31 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Tislelizumab, Lenvatinib Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma NCT07014150Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Lenvatinib, Iparomlimab and Tuvonralimab Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC NCT07018947Phase 212 sites📍 Badalona📍 Barcelona📍 Barcelona Fundacion Clinic per a la Recerca Biomédica · Tests: Atezolizumab and Bevacizumab Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence NCT06954116Phase 21 site📍 Wuhan Tongji Hospital · Tests: Iparomlimab and Tuvonralimab (QL1706), Partial hepatectomy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy